Comparison of treatment strategies for femoro‐popliteal disease: A network meta‐analysis. Issue 7 (14th January 2018)

• Record Type: Journal Article
• Authors: Koifman, Edward; Lipinski, Michael J.; Buchanan, Kyle; Yu Kang, Won; Escarcega, Ricardo O.; Waksman, Ron; Bernardo, Nelson L.
• Is Part Of: Catheterization and cardiovascular interventions. Volume 91:Issue 7(2018)
• Page Start: 1320
• Page End: 1328
• Publication Date: 2018-01-14
• Subjects: outcome -- peripheral artery disease -- target lesion revascularization; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.27484
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Objectives: We sought to compare treatment strategies in a Bayesian network meta‐analysis of randomized controlled trials. Background: Peripheral artery disease (PAD) is a prevalent morbidity that is treated with various strategies. Methods: We performed a MEDLINE search for randomized studies comparing at least 2 treatment strategies, including bypass surgery, percutaneous transluminal angioplasty (PTA) balloons, stents, covered stents, drug‐eluting stents (DES), and drug‐coated balloons (DCB), in patients with native femoro‐popliteal disease. Mixed treatment comparison model generation was performed to directly and indirectly compare the strategies in terms of restenosis and target lesion revascularization (TLR) presented as odds ratios (OR, [95% credible intervals]). Results: Twenty‐nine studies with 4, 820 patients were included in the present study. PTA was the largest group with 1, 900 patients, followed by DCB ( n = 1, 343), bare metal stents ( n = 941), covered stents ( n = 304), DES ( n = 236), and bypass ( n = 92). Mean age was 68 ± 9 years, 64% were male, 37% diabetic, and 55% smokers. Mean lesion length was 77 ± 44 mm, and 39% were total occlusions. Bayesian hierarchical random‐effects model demonstrated all treatments were significantly better than, or had a trend toward superiority over, PTA, with DCB ranking well in both restenosis (OR = 0.29, [0.17‐0.47]) and TLR (OR = 0.31, [0.20‐0.46]). Nonetheless, none of the therapies showed superiority in terms of survival or amputations. Conclusion: Treatment of femoro‐popliteal disease has significantly evolved in recent years, with higher rates of patency and freedom from TLR. However, the utility of these treatment strategies in terms of reduction of amputations and overall survival remains in question.